Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess Sells 5,000 Shares

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 5,000 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the sale, the director now owns 16,641 shares of the company’s stock, valued at $832,050. This trade represents a 23.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Robert Chess also recently made the following trade(s):

• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total value of $181,682.40.
• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The shares were sold at an average price of $47.26, for a total value of $170,136.00.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock opened at $43.60 on Friday. The stock has a 50-day simple moving average of $46.35 and a 200-day simple moving average of $46.46. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of -12.11 and a beta of 1.85.

Wall Street Analyst Weigh In

Several brokerages have commented on TWST. Robert W. Baird raised their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Wolfe Research assumed coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Finally, Evercore ISI increased their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.90.

Institutional Trading of Twist Bioscience

Several large investors have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at $34,000. Signaturefd LLC raised its position in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. DekaBank Deutsche Girozentrale bought a new position in shares of Twist Bioscience in the second quarter valued at approximately $61,000. Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience during the 3rd quarter worth $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.